TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year

Mar.03
TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year
Turning Point Brands, a U.S. nicotine and tobacco-related consumer products company, reported its fiscal 2025 fourth-quarter results: quarterly revenue was $121 million, up 29% year over year; adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) was $30 million, up 14%. Net revenue from modern oral nicotine products was $41.3 million, up 266% year over year.

Key Takeaways

 

  • March 2, 2026: TPB released highlights from its fiscal 2025 fourth-quarter results;
  • Q4 revenue: $121 million, up 29% year over year;
  • Modern Oral net revenue: $41.3 million, up 266% year over year;
  • Adjusted EBITDA: $30 million, up 14%, with a 24.8% margin;
  • 2026 Modern Oral guidance: gross sales of $220–$240 million; net sales of $180–$190 million.

2Firsts, March 3, 2026

 

According to GuruFocus News, Turning Point Brands, a U.S. nicotine and tobacco-related consumer products company, released key highlights from its fiscal 2025 fourth-quarter results. The company said Q4 revenue increased 29% year over year to $121 million.

 

The company reported that adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization, EBITDA) rose 14% year over year to $30 million, representing a 24.8% margin. Gross margin was 55.9%, flat versus the same period last year. Q4 SG&A expenses were $47.7 million, up $3.1 million from the prior quarter.

 

By segment, the Stoker’s segment (including modern nicotine pouches, traditional oral tobacco, and chewing tobacco) posted Q4 net sales of $81 million, up 70% year over year. The Zig-Zag segment (rolling papers) recorded Q4 net sales of $40 million, down 13% year over year. The company said the Modern Oral segment posted Q4 net revenue of $41.3 million, up 266% year over year.

 

On cash flow and capital expenditures, the company reported Q4 free cash flow of $19.2 million. Quarterly capital expenditures (CapEx) were $3.3 million, and ending cash balance was $222.8 million.

 

The company also provided 2026 guidance: Modern Oral gross sales are projected at $220–$240 million, and Modern Oral net sales at $180–$190 million. It also guided for Q1 2026 EBITDA of $24–$27 million. The company further disclosed a forward-looking effective income tax rate range of 23%–26%, and a 2026 CapEx budget of $4–$5 million (excluding Modern Oral projects).

 

Regarding business progress and risk factors, the company said it is expanding its distribution network, with ALP nicotine pouches appearing in brick-and-mortar retail stores ahead of schedule. It also said it will make strategic investments in sales and marketing, including expanding its sales force and improving its online presence. The company noted that ongoing sales and marketing investments make it challenging to accurately forecast EBITDA beyond the first quarter, and warned that potential tax increases on nicotine pouches could affect pricing and promotional strategies. It also said elevated tariff rates have impacted gross margins in the Stoker’s segment.

 

 

Image Source:yahoofinance

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | ZYN Adds Tropical Flavor and Expands 1.5mg Nicotine Options in the Philippines
Product | ZYN Adds Tropical Flavor and Expands 1.5mg Nicotine Options in the Philippines
ZYN has expanded its nicotine pouch portfolio in the Philippines with the addition of Cool Breeze 1.5mg and Tropical in 3mg and 6mg strengths. Public information shows that 1.5mg is among the lower nicotine strengths offered by ZYN in the Philippine market and is positioned for adult nicotine consumers who are new to nicotine pouches.
PMI
Jun.08
 Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
According to Reuters, Philip Morris International (PMI) lowered its 2026 adjusted earnings-per-share forecast amid regulatory uncertainty around Zyn nicotine pouches, rising competition and shipment pressure in the U.S. market.
PMI
Jun.02
KT&G Q1 2026 Financial Results: Revenue at $1.156 Billion, E-Cigarettes to Launch Independent Overseas Expansion
KT&G Q1 2026 Financial Results: Revenue at $1.156 Billion, E-Cigarettes to Launch Independent Overseas Expansion
KT&G reports a 27.6% increase in Q1 operating profit, with traditional and new tobacco sectors driving growth.
May.07 by 2FIRSTS.ai
Malaysian Tobacco Control Groups Call for Annual 5% Tobacco Tax Hike
Malaysian Tobacco Control Groups Call for Annual 5% Tobacco Tax Hike
According to The Star and The Edge Malaysia, tobacco control groups in Malaysia have urged the government to raise tobacco taxes by at least 5% annually, saying the measure could reduce smoking rates and fund public health and social programmes.
News
May.26
2Firsts Data|China Vape Exports Sink to Three-Year April Low After Tax Rebate Ends, Falling to $694 Million
2Firsts Data|China Vape Exports Sink to Three-Year April Low After Tax Rebate Ends, Falling to $694 Million
China’s e-cigarette export value declined to $694 million in April 2026, marking the lowest April level in the past three years. The data is notable because April was the first full month after China removed export VAT rebates for certain e-cigarette products. Compared with April 2025, export value fell 20.9%; compared with April 2024, it was down 22.3%. Month-on-month, exports dropped 23.2% from March 2026.
Special Report
May.23
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
Ahead of World No Tobacco Day 2026, WHO released its first global report on nicotine pouches, warning that rapid market growth, youth-oriented marketing and weak regulation are converging. 2Firsts views the report as an important warning, but not a complete risk assessment, with harm-reduction questions still unresolved.
Special Report
May.17